|Source||Humanized (from mouse)|
|Pronunciation||ben" ra liz' ue mab|
|Main uses||Eosinophilic asthma|
|Side effects||Headache, sore throat|
|Typical dose||30 mg|
|Chemical and physical data|
|Molar mass||146056.45 g·mol−1|
Benralizumab, sold under the brand name Fasenra, is a medication used to treat eosinophilic asthma. It may be used in those not controlled with inhaled corticosteroids and a long-acting beta-agonist. It is given by injection under the skin.
Common side effects include headache and sore throat. Other side effects may include anaphylaxis or hives. Safety in pregnancy is unclear. It is a monoclonal antibody that binds to interleukin-5 receptors (CD125) on eosinophils, resulting in their destruction.
Benralizumab was approved for medical use in the United States in 2017 and Europe in 2018. In the United Kingdom it costs the NHS about £2,000 per dose as of 2021. This amount is about 5,200 USD in the United States.
It is give at a dose of 30 mg every 4 weeks for three doses, than every 8 weeks.
Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016. It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe eosinophilic asthma. It was granted designation as an orphan drug by the Food and Drug Administration for treatment of eosinophilic oesophagitis in August 2019.
- "Fasenra EPAR". European Medicines Agency (EMA). Archived from the original on 18 October 2020. Retrieved 13 October 2020.
- "DailyMed - FASENRA- benralizumab injection, solution". dailymed.nlm.nih.gov. Archived from the original on 13 May 2021. Retrieved 9 January 2022.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 284. ISBN 978-0857114105.
- "Fasenra Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 9 January 2022.
- "AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016". Archived from the original on 2016-10-11. Retrieved 2021-03-04.
- Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. (June 2017). "Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma". The New England Journal of Medicine. 376 (25): 2448–2458. doi:10.1056/NEJMoa1703501. PMID 28530840.
- "Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma". AstraZeneca. 2017-11-14. Archived from the original on 2018-11-07. Retrieved 2021-03-04.
- "Fasenra granted US Orphan Drug Designation for eosinophilic oesophagitis". www.astrazeneca.com. Archived from the original on 2019-10-29. Retrieved 2019-10-29.